Objective:

To evaluate the efficacy of photobiomodulation (PBM) therapy in delaying the progression of dry age-related macular degeneration (AMD) through a double-masked, randomized, sham-controlled study.

Approach:

Key Findings:

• PBM therapy resulted in significant improvements in best-corrected visual acuity (BCVA) and reduction in macular drusen volume, indicating its potential as a therapeutic option.
• The Valeda Light Delivery System, using multiwavelength PBM, received FDA approval as the first treatment for vision loss in dry AMD, marking a significant advancement in AMD management.
• PBM showed potential benefits in reducing inflammation and oxidative stress markers associated with AMD, which are critical factors in disease progression.

Interpretation:

PBM therapy may offer a promising noninvasive treatment option for patients with early to intermediate stages of dry AMD, potentially delaying disease progression and improving visual outcomes, thus enhancing patient quality of life.

Limitations:

• Previous studies lacked control groups and had short follow-up durations, which may limit the reliability of the findings.
• Variability in disease stages among participants may affect the generalizability of results, necessitating caution in applying these findings broadly.

Conclusion:

PBM therapy represents a novel approach to managing dry AMD, with evidence suggesting it can improve visual function and reduce disease markers, highlighting the need for further research to confirm these findings.

Sources:

• LIGHTSITE I Trial
Attribution Notice

This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.